Category: DECN

DECN – DECISION DIAGNOSTICS UPDATE

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options

New York, New York–(Newsfile Corp. – February 7, 2021) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (Other OTC:DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $300,000 investing in Decision Diagnostics stock or options between March 3, 2020 and December 17, 2020 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DECN.

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/02/73831_d93b9e2174b96b3b_001.jpg

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6455/73831_d93b9e2174b96b3b_001full.jpg

There is no cost or obligation to you.

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/02/73831_d93b9e2174b96b3b_002.jpg

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6455/73831_d93b9e2174b96b3b_002full.jpg

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) the Company could not meet the FDA’s emergency use authorization (“EUA”) testing requirements for its purported COVID-19 test; (3) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (4) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Specifically, on December 17, 2020, the Securities and Exchange Commission (“SEC”) filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the “SEC Complaint”). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics’ COVID-19 device and progress towards achieving FDA EUA for that device. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company’s stock.

Following the filing of the SEC Complaint, Decision Diagnostics’ common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Decision Diagnostics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73831

info

DECN – DECN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 16, 2021 in the Class Action Filed on Behalf of Decision Diagnostics Corp. Limited Shareholders

New York, New York–(Newsfile Corp. – February 3, 2021) – The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Decision Diagnostics Corp. (OTC: DECN) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/02/73645_743166_logo.jpg

Class Period: March 3, 2020 and December 17, 2020
Lead Plaintiff Deadline: March 16, 2021

Learn more about your recoverable losses in DECN:
http://www.kleinstocklaw.com/pslra-1/decision-diagnostics-corp-loss-submission-form?id=12679&from=5

The filed complaint alleges that Decision Diagnostics Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (ii) the Company could not meet the FDA’s EUA testing requirements for its purported COVID-19 test; (iii) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (iv) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Shareholders have until March 16, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

For additional information about the DECN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73645

info

DECN – Decision Diagnostics Class Action Reminder

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options

New York, New York–(Newsfile Corp. – January 29, 2021) – If you suffered losses exceeding $300,000 investing in Decision Diagnostics stock or options between March 3, 2020 and December 17, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/DECN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/73233_56d437b2b45e0846_001.jpg

There is no cost or obligation to you.

Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (OTC: DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/73233_56d437b2b45e0846_002.jpg

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/73233_56d437b2b45e0846_003.jpg

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) the Company could not meet the FDA’s emergency use authorization (“EUA”) testing requirements for its purported COVID-19 test; (3) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (4) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Specifically, on December 17, 2020, the Securities and Exchange Commission (“SEC”) filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the “SEC Complaint”). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics’ COVID-19 device and progress towards achieving FDA EUA for that device. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company’s stock.

Following the filing of the SEC Complaint, Decision Diagnostics’ common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Decision Diagnostics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73233

info

DECN – Decision Diagnostics Shareholder Alert

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options

New York, New York–(Newsfile Corp. – January 19, 2021) –  If you suffered losses exceeding $300,000 investing in Decision Diagnostics stock or options between March 3, 2020 and December 17, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/DECN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/72377_a018ac7ac44e0b37_001.jpg

There is no cost or obligation to you.

Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (OTC:DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/72377_a018ac7ac44e0b37_002.jpg

Cannot view this image? Visit: https://www.elitestockchat.com/wp-content/uploads/2021/01/72377_a018ac7ac44e0b37_003.jpg

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) the Company could not meet the FDA’s emergency use authorization (“EUA”) testing requirements for its purported COVID-19 test; (3) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (4) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Specifically, on December 17, 2020, the Securities and Exchange Commission (“SEC”) filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the “SEC Complaint”). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics’ COVID-19 device and progress towards achieving FDA EUA for that device. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company’s stock.

Following the filing of the SEC Complaint, Decision Diagnostics’ common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Decision Diagnostics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72377

info

DECN – SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Decision Diagnostics Corp. (“Decision Diagnostics” or “the Company”) (OTC: DECN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between March 3, 2020 and December 17, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before March 16, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the FDA’s EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Decision Diagnostics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

DECN – Pomerantz Law Firm Announces the Filing of a Class Action against Decision Diagnostics Corporation and Certain Officers – DECN

NEW YORK, Jan. 15, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation (“Decision Diagnostics” or the “Company”) (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Decision Diagnostics securities between March 3, 2020 and December 17, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Decision Diagnostics securities during the Class Period, you have until March 16, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Decision Diagnostics purportedly offers, among other products and services, prescription and non-prescription diagnostics and home testing products.

From March 2020 to at least June 2020, Defendants claimed that the Company had developed a finger-prick blood test that could detect COVID-19 in less than one minute. Defendants also made various representations regarding the Company’s progress towards achieving U.S. Food and Drug Administration (“FDA”) emergency use authorization (“EUA”) for this purported COVID-19 finger-prick blood test.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and failed to disclose to investors that: (i) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (ii) the Company could not meet the FDA’s EUA testing requirements for its purported COVID-19 test; (iii) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (iv) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On December 17, 2020, the SEC filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the “SEC Complaint”). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics’ COVID-19 device and progress towards achieving FDA EUA for that device.  As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device.  The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company’s stock.

Following the filing of the SEC Complaint, Decision Diagnostics’ common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby

Pomerantz LLP
[email protected] 

888-476-6529 ext. 7980

SOURCE Pomerantz LLP

Related Links

www.pomerantzlaw.com

DECN – SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Decision Diagnostics Corp. (DECN) and Encourages DECN Investors to Contact the Firm

PHILADELPHIA, Dec. 19, 2020 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Decision Diagnostics Corp. (“Decision Diagnostics”) (OTC: DECN) on behalf of the company’s stockholders.
On December 17, 2020, the U.S. Securities and Exchange Commission (“SEC”) filed a complaint against Decision Diagnostics and its Chief Executive Officer (“CEO”), Keith Berman, in the U.S. District Court for the Southern District of New York. The complaint alleges that Decision Diagnostics and Berman seized upon the Covid-19 global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute.According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics’ Covid-19 device and progress towards FDA emergency use authorization. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. Further, its advisors had warned that the testing kit they were trying to manufacture would not work as Decision Diagnostics had described. The complaint also alleges that the statements created the misleading impression that the test was soon to be introduced to the market and led to surges in the price and trading volume of Decision Diagnostics’ stock.Decision Diagnostics’ investors are encouraged to contact Kaskela Law LLC at https://kaskelalaw.com/case/decision-diagnostics-corp/ for additional information about this investigation and their legal rights and options.Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.CONTACT:D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com